Form 4: Cadrenal Therapeutics COO Acquires Stock Options
SEC Form 4 Filing
Jeffrey Scott Cole, Chief Operating Officer of Cadrenal Therapeutics, Inc., acquired options to purchase 150,000 shares of common stock on April 2, 2024.
Summary
- On April 2, 2024, Jeffrey Scott Cole, the Chief Operating Officer of Cadrenal Therapeutics, Inc., was granted options to purchase 150,000 shares of the company's common stock.
- The exercise price of these options is $0.62 per share.
- The options vest in four installments, with the first 1/4 vesting on April 1, 2025, and the remainder vesting pro rata monthly over the following three years, contingent upon continued service to the Issuer.
- The options expire on April 1, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, indicating a neutral sentiment.
Industry Context
This is a standard practice for incentivizing and retaining key executives in publicly traded companies.
Key Dates
| Date | Description |
|---|---|
| 04/02/2024 | Date of transaction: COO Jeffrey Scott Cole acquired stock options. |
| 04/01/2025 | First vesting date for 1/4 of the stock options. |
| 04/01/2034 | Expiration date of the stock options. |
| 04/03/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.